



# **Immedica's partner Actinium presented four abstracts of Iomab-B at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®**

**Stockholm, February 27, 2024** – Immedica's partner Actinium Pharmaceuticals, Inc. presented four abstracts at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT® (American Society for Transplantation and Cellular Therapy) and CIBMTR® (Center for International Blood and Marrow Transplant Research) on February 21 – 24, 2024 in San Antonio, Texas. Two oral presentations and two poster presentations highlighted results from the positive Phase 3 SIERRA trial of Iomab-B (<sup>131</sup>I-Apamistamab). Altogether 10 oral presentations of the SIERRA results have been presented across the US and Europe since they were first reported at the 2023 Tandem Meetings.

## **Oral presentations:**

Title: <sup>131</sup>I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML

Title: Targeted Myeloablative Radiation Using <sup>131</sup>I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust Engraftment

## **Poster presentations:**

Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with <sup>131</sup>I-Apamistamab Prior to HCT in Patients with R/R AML

<sup>131</sup>I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes

## **About the TCT Tandem Meetings**

The Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). Administrators, clinicians, data manager / clinical research professionals, fellows-in-training, investigators, laboratory technicians, MD/PhDs, nurses, nurse practitioners, pharmacists, physician assistants, and other allied health professional attendees benefit from a full scientific program that addresses the most timely issues in hematopoietic cell transplantation and cellular therapy.

## **About Actinium Pharmaceuticals, Inc.**

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. Actinium's clinical pipeline is led by targeted radiotherapies that are being applied to targeted conditioning, which is intended to selectively deplete a

patient's disease or cancer cells and certain immune cells prior to a hematopoietic stem cell transplantation, gene therapy or adoptive cell therapy, such as CAR-T, to enable engraftment of these transplanted cells.

For more information, please visit: <http://www.actiniumpharma.com>

### **About Immedica**

Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica's capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica's therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.

Immedica was founded in 2018 by the investment company Impilo and Buy-in-Management. Today Immedica employs more than 100 people across Europe and the Middle East.

For more information visit [www.immedica.com](http://www.immedica.com)

### **Immedica contact:**

Linda Holmström  
Head of Communication  
[linda.holmstrom@immedica.com](mailto:linda.holmstrom@immedica.com)  
+ 46 708 73 40 95

Immedica Pharma AB  
Solnavägen 3H  
SE-113 63 Stockholm